Metabolic syndrome and prostate cancer in Afro-Caribbean men.
Afro-Caribbean
metabolic syndrome
prostate cancer
radical prostatectomy
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
07
09
2021
accepted:
29
11
2021
pubmed:
15
12
2021
medline:
23
2
2022
entrez:
14
12
2021
Statut:
ppublish
Résumé
Metabolic syndrome (MetS) is a group of risk factors that increases the likelihood of developing cardiovascular diseases. Although suggested, the relationship between MetS and prostate cancer (PCa) is still inconclusive. Very few studies have addressed this question in populations of African descent, which are disproportionately affected by PCa. This study aimed to assess the prevalence of MetS among incident cases of Afro-Caribbean PCa and estimate its association with adverse clinicopathological features and the risk of biochemical recurrence (BCR) after radical prostatectomy (RP). We included 285 consecutive patients with incident cases of PCa attending the University Hospital of Guadeloupe (French West Indies). MetS was evaluated at the time of diagnosis by collecting information on blood pressure, glycaemic status, triglyceride and high-density lipoprotein cholesterol levels, and obesity through various surrogates, including two waist circumference indicators (≤94 cm, ≥102 cm), the waist-to-hip ratio (≥0.95), and body mass index (BMI; ≥30 kg/m The prevalence of MetS varied greatly, from 31.6% to 16.4%, when a waist circumference ≥94 cm or BMI were used as obesity surrogates, respectively. No significant associations were found between MetS, regardless of the obesity criteria employed, and the risk of adverse pathological features or BCR. The high variability in MetS resulting from the diversity of obesity criteria used may explain the discordant associations reported in the literature. Further studies using strict and uniform criteria to define MetS on homogeneous ethnic groups are encouraged to clarify the association, if any, between MetS and PCa outcomes.
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
359-365Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol. 2012;61:1079-1092.
Hsing AW, Chokkalingam AP. Prostate cancer epidemiology. Front Biosci. 2006;11:1388-1413.
Damber JE, Aus G. Prostate cancer. Lancet. 2008;371:1710-1721.
Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest? Epidemiol Rev. 2001;23:3-13.
Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-1645.
Russo A, Autelitano M, Bisanti L. Metabolic syndrome and cancer risk. Eur J Cancer. 2008;44(2):293-297.
Uzunlulu M, Telci Caklili O, Oguz A. Association between Metabolic Syndrome and Cancer. Ann Nutr Metab. 2016;68(3):173-179.
Campi R, Brookman-May SD, Subiela Henríquez JD, et al. Impact of metabolic diseases, drugs, and dietary factors on prostate cancer risk, recurrence, and survival: a systematic review by the European Association of Urology Section of Oncological Urology. Eur Urol Focus. 2019;5(6):1029-1057.
Gacci M, Russo GI, De Nunzio C, et al. Meta-analysis of metabolic syndrome and prostate cancer. Prostate Cancer Prostatic Dis. 2017;20:146-155.
Esposito K, Chiodini P, Capuano A, et al. Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Invest. 2013;36:132-139.
Hsing AW, Sakoda LC, Chua SC. Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007;86:s843-s857.
Xiang YZ, Xiong H, Cui ZL, et al. The association between metabolic syndrome and the risk of prostate cancer, high-grade prostate cancer, advanced prostate cancer, prostate cancer-specific mortality and biochemical recurrence. J Exp Clin Cancer Res. 2013;32(1):9.
Hammarsten J, Damber JE, Haghsheno MA, Mellström D, Peeker R. A stage-dependent link between metabolic syndrome components and incident prostate cancer. Nat Rev Urol. 2018;15(5):321-333.
Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol. 2006;164(11):1094-1102.
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 1998;15:539-553.
National Cholesterol Education Program (NCEP): Expert Panel on Detection and Treatment of High Blood Cholesterol in Adults. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute scientific statement. Circulation. 2005;112:2735-2752.
Sumner AE, Finley KB, Genovese DJ, Criqui MH, Boston RC. Fasting triglyceride and the triglyceride-HDL cholesterol ratio are not markers of insulin resistance in African Americans. Arch Intern Med. 2005;27(165):1395-1400.
Sumner AE, Vega GL, Genovese DJ, Finley KB, Bergman RN, Boston RC. Normal triglyceride levels despite insulin resistance in African Americans: role of lipoprotein lipase. Metabolism. 2005;54:902-909.
Osei K, Schuster D. Effects of ethnicity and race on insulin sensitivity, ambulatory blood pressure and heart rates in three ethnic populations: comparative studies in African Americans, Ghanaian immigrants and White Americans. Am J Hypertens. 1996;9:1157-1164.
Cowie CC, Casagrande SS, Geiss LS. Prevalence and incidence of type 2 diabetes and prediabetes. In: Cowie CC, Casagrande SS, Menke A, eds. Diabetes in America. 3rd ed. National Institutes of Health; 2018;3-1-3-32.
Gaillard T, Schuster D, Osei K. Metabolic syndrome in Black people of the African diaspora: the paradox of current classification, definition and criteria. Ethn Dis. 2009;19(2, Suppl 2):S2-S7.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
Deloumeaux J, Bhakkan B, Eyraud R, et al. Prostate cancer clinical presentation, incidence, mortality and survival in Guadeloupe over the period 2008-2013 from a population-based cancer registry. Cancer Causes Control. 2017;28(11):1265-1273.
Ma WY, Yang CY, Shih SR, et al. Measurement of waist circumference: midabdominal or iliac crest? Diabetes Care. 2013;36:1660-1666.
Cameron N. The measurement of human growth. In: Cameron N, Bogin B, eds. Human growth and development. 2nd ed. Elsevier Inc.; 2012;487-513.
Rothman K, Greenland S. Introduction to stratified analysis. In: Rothman K, Greenland S, eds. Modern epidemiology. Lippincott-Raven; 1998:253-279.
Holm S. A Simple sequentially rejective multiple test procedure. Scand J Statist. 1979;6:65-70.
Beebe-Dimmer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA. Features of the metabolic syndrome and prostate cancer in African-American men. Cancer. 2007;109(5):875-881. doi:10.1002/cncr.22461
Beebe-Dimmer JL, Nock NL, Neslund-Dudas C, et al. Racial differences in risk of prostate cancer associated with metabolic syndrome. Urology. 2009;74(1):185-190.
Post JM, Beebe-Dimmer JL, Morgenstern H, et al. The metabolic syndrome and biochemical recurrence following radical prostatectomy. Prostate Cancer. 2011;2011:245642.